Drug-induced arrhythmias

Critical Care Medicine

Volumn 38, Issue 6 SUPPL., 2010, Pages

  Barnes, Brian J ^a   Hollands, James M ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Anesthetic agents; Antiarrhythmics; Arrhythmias; Bronchodilators; Digoxin; Drug induced; Electrolyte imbalances; Inotropes; Patient safety; QT interval; Risk factors

Indexed keywords

AMIODARONE; ANESTHETIC AGENT; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; ARSENIC TRIOXIDE; BEPRIDIL; BRONCHODILATING AGENT; CHLORPROMAZINE; CISAPRIDE; CLARITHROMYCIN; DIGOXIN; DISOPYRAMIDE PHOSPHATE; DOFETILIDE; DROPERIDOL; GASTROINTESTINAL AGENT; IBUTILIDE FUMARATE; INOTROPIC AGENT; MAGNESIUM; NARCOTIC AGENT; NEUROLEPTIC AGENT; POTASSIUM; PROCAINAMIDE; QUINIDINE; QUINIDINE GLUCONATE; QUINIDINE POLYGALACTURONATE; SOTALOL; SUXAMETHONIUM; UNINDEXED DRUG;

BRADYCARDIA; CARDIOVASCULAR DISEASE; CRITICALLY ILL PATIENT; DRUG FATALITY; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART FAILURE; HEART RATE; HUMAN; HYPERKALEMIA; HYPERMAGNESEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY DYSFUNCTION; LONG QT SYNDROME; MYOPATHY; NONHUMAN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STRATEGIC PLANNING; TACHYCARDIA; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 77953029798     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de112a     Document Type: Article

References (95)

1. Sanoski CA, Schoen MD, Bauman JL: The arrhythmias. In: Pharmacotherapy: A Pathophysiologic Approach. Seventh Edition. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Eds). New York, The McGraw-Hill Companies, 2008, pp 279-314
2. Roden DM, Balser JR, George AL, et al: Cardiac ion channels. Annu Rev Physiol 2002; 64:431-475
3. Mines GR: On circulating excitations in heart muscle and their possible relation to tachycardia and fibrillation. Trans R Soc Canada 1914; 8:43-52
4. DeSilva RA: "George Ralph Mines," ventricular fibrillation and the discovery of the vulnerable period. J Am Coll Card 1997; 29: 1397-1402
5. Weisberg LS: Management of severe hyperkalemia. Crit Care Med 2008; 36:3246-3251
6. Cohn JN, Kowey PR, Whelton PK, et al: New guidelines for potassium replacement in clinical practice. Arch Intern Med 2000; 160: 2429-2436
7. Owen P, Monahan MF, MacLaren R: Implementing and assessing an evidence-based electrolyte dosing order form in the medical ICU. Intensive Crit Care Nurs 2008; 24:8-19
8. Diercks DB, Shumaik GM, Harrigan RA, et al: Electrocardiographic manifestatioins: Electrolyte abnormalities. J Emerg Med 2004; 27:153-160
9. Fisch C: Relation of electrolyte disturbances to cardiac arrhythmias. Circulation 1973; 47: 408-419
10. Freedman BI, Burkart JM: Hypokalemia. Crit Care Clin 1991; 7:143-153
11. Dacey MJ: Hypomagnesemic disorders. Crit Care Clin 2001; 17:155-173
12. Purvis JR, Movahed A: Magnesium disorders and cardiovascular diseases. Clin Cardiol 1992; 15:556-568
13. Whang R, Flink EB, Dyckner R, et al: Magnesium depletion as a cause of refractory potassium depletion. Arch Intern Med 1985; 145:1686-1689
14. Van Hook JW: Hypermagnesemia. Crit Care Clin 1991; 7:215-223
15. Kannankeril PJ, Roden DM: Drug-induced long QT and torsade de pointes: Recent advances. Curr Opin Cardiol 2007; 22:39-43
16. Roden DM, Lazzara R, Rosen M, et al: Multiple mechanisms in the long-QT syndrome. Circulation 1996; 94:1996-2012
17. Buggisch D, Isenberg G, Ravens U, et al: The role of sodium channels in the effects of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated mammalian heart preparations. Eur J Pharmacol 1985; 118:303-311
18. Ficker E, Kuryshev YA, Dennis AT, et al: Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 2004; 66:33-44
19. Kuryshev YA, Ficker E, Wang L, et al: Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005; 312:316-323
20. Antzelevitch C: Hetergeneity of cellular repolarization of LTQS. The role of M cells. Eur Heart J 2001; 3:K2-K16
21. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022
22. Arizona Center for Education and Research on Therapeutics. Available at www.qtdrugs.org. Accessed October 20, 2009
23. Molokhia M, Pathak A, Lapeyre-Mestre M, et al: Case ascertainment and estimated incidence of drug-induced long-QT syndrome: Study in Southwest France. Br J Clin Pharmacol 2008; 66:386-395
24. Freeman BD, Dixon DJ, Coopersmith CM, et al: Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiol Drug Saf 2008; 17:971-981
25. Tzivoni D, Banai S, Schuger C, et al: Treatment of torsades de pointes with magnesium sulfate. Circulation 1988; 77:392-397
26. Lin YL, Kung MF: Magnitude of QT prolongation associated with a higher risk of torsades de pointes. Pharmacoepidemol Drug Saf 2009; 18:235-239
27. Bazett HC: An analysis of the timerelations of electrocardiograms. Heart 1920; 7:353-370
28. Fridericia LS: Die Systolendauer im Elektrokardiogramm bei normalen Menchan und bei Herzdranken. Acta Med Scand 2002; 53: 469-486
29. Desai M, Li L, Desta Z, et al: Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2003; 55: 511-517
30. Moss AJ: Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol 1993; 72: 23B-25B
31. Drew BJ, Ackerman MJ, Funk M, et al: Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121:1047-1060
32. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412
33. Echt DS, Liebson PR, Mitchell LB, et al: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991; 324:781-788
34. Siebels J, Cappato R, Ruppel R, et al: Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993; 73: 109F-113F
35. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990; 82:1106-1116
36. Morganroth J, Goin JE: Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis. Circulation 1991; 84: 1977-1983
37. Doig JC: Drug-induced cardiac arrhythmias: Incidence, prevention and management. Drug Saf 1997; 17:265-275
38. Chamberlain DA, Jewitt DE, Julian DG, et al: Oral mexiletine in high-risk patients after myocardial infarction. Lancet 1980; 2:1324-1327
39. Cairns JA, Connolly SJ, Roberts R, et al: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349:675-682
40. Burkart F, Pfisterer M, Kiowski W, et al: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16:1711-1718
41. Waldo AL, Camm AJ, deRuyter H, et al: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348:7-12
42. Julian DG, Jackson FS, Prescott RJ, et al: Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1:1142-1146
43. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583
44. Petersen JW, Felker GM: Inotropes in the management of acute heart failure. Crit Care Med 2008; 36:S106-S111
45. Coma-Canella I: Changes in plasma potassium during the dobutamine stress test. Int J Cardiol 1991; 33:55-59
46. Romson JL, Leung JM, Bellows WH, et al: Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiac surgical patients. Anesthesiology 1999; 91:1318-1328
47. De Backer D, Creteur J, Dubois MJ, et al: The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 2006; 34:403-408
48. Kulka PJ, Tryba M: Inotropic support of the critically ill patient: A review of the agents. Drugs 1993; 45:654-667
49. Nelson SD, Coyne K: Electrophysiologic effects of selective B1 adrenergic stimulation in the late phase of myocardial infarct healing. Int J Cardiol 1992; 36:95-102
50. Secknus MA: Evolution of dobutamine echocardiography protocols and indications: Safety and side effects in 3,011 studies over 5 years. J Am Coll Cardiol 1997; 29:1234-1240
51. Dobutrex [package insert]. Bedford, OH, Bedford Laboratories, 2007
52. Cuffe MS, Califf RM, Adams KF Jr, et al: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 2002; 287: 1541-1547
53. Fleming GA, Murray KT, Yu C, et al: Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation 2008; 118:1619-1625
54. Seino Y, Momomura S, Takano T, et al: Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Crit Care Med 1996; 24: 1490-1497
55. Primacor [package insert]. Barceloneta, PR, Searle Ltd, 1999
56. Ma G, Brady WJ, Pollack M, et al: Electrocardiographic manifestations: Digitalis toxicity. J Emerg Med 2001; 20:145-152
57. Bauman JL, DiDomenico RJ, Galanter WL: Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs 2006; 6:77-86
58. Kelly RA, Smith TW: Recognition and management of digitalis toxicity. Am J Cardiol 1992; 69:108G-119G
59. Wofford JL, Wttinger WH" Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med 1991; 9(Suppl 1): 11-15
60. Antman EM, Wenger TL, Butler VP Jr, et al: Treatment of 150 cases of life-threatening digitalis intoxications with digoxin-specific Fab antibody fragments: final report of a multicenter study. Circulation 1990; 81: 1744-1752
61. DigiBind [package insert]. Research Triangle Park, NC, GlaxoSmithKline, 2003
62. Kraft MD, Btaiche IF, Sacks GS, et al: Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm 2005; 62:1663-1682
63. Mandal AK: Hypokalemia and hyperkalemia. Med Clin North Am 1997; 81:611-639
64. Katz RL, Katz GJ: Surgical infiltration of pressor drugs and their interaction with volatile anaesthetics. Br J Anaesth 1966; 38: 712-718
65. Reynolds AK: On the mechanism of myocardial sensitization to catecholamines by hydrocarbon anesthetics. Can J Physiol Pharmacol 1984; 62:183-198
66. Cárceles MD, Laorden ML, Hernandez J, et al: Halothane, isoflurane and enflurane potentiate the effect of noradrenaline on ventricular automaticity in the rat heart: Evidence of the involvement of both alphaor beta-adrenoceptors. J Pharm Pharmacol 1993; 42:186-190
67. Moore AM, Weiskopf RB, Eger EI, et al: Arrhythmogenic doses of epinephrine are similar during desflurane or isoflurane anesthesia in humans. Anesthesiology 1993; 79: 943-947
68. Navarro R, Weiskopf RB, Moore MA, et al: Humans anesthetized with sevoflurane or isoflurane have similar arrhythmic response to epinephrine. Anesthesiology 1994; 80: 545-549
69. Atlee JL 3rd, Bosnjak ZJ: Mechanisms for cardiac dysrhythmias during anesthesia. Anesthesiology 1990; 72:347-74
70. Hüneke R, Fassl J, Roissant R, et al: Effects of volatile anesthetics on cardiac ion channels. Acta Anaesthesiol Scan 2004; 48: 547-561
71. Himmel HM: Mechanisms involved in cardiac sensitization by volatile anesthetics: General applicability to halogenated hydrocarbons? Crit Rev Toxicol 2008; 38:773-780
72. Shibata S, Ono K, Iijima T: Sevoflurane inhibition of the slowly activating delayed rectifier K+ current in guinea-pig ventricular cells. J Pharmacol Sci 2004; 95:363-373
73. Kang J, Reynolds WP, Chen XL, et al: Mechanisms underlying the QT interval-prolonging effects of sevoflurane and its interactions with other QT-prolonging drugs. Anesthesiology 2006; 104:1015-1022
74. Chen XD, Yamakage M, Yamada Y, et al: Inhibitory effects of volatile anesthetics on currents produced on heterologous expression of KvLQT1 and minK in Xenopus oocytes. Vasc Pharmacol 2002; 39:33-38
75. Suzuki A, Bosnjak ZJ, Kwok WM: The effects of isoflurane on the cardiac slowly activating delayed-rectifier potassium channel in guinea-pig ventricular myocytes. Anesth Analg 2003; 96:1308-1315
76. Schmeling WT, Warltier DC, McDonald DJ, et al: Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991; 72:137-144
77. Kuenszberg E, Loeckinger A, Kleinsasser A, et al: Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000; 17:662-664
78. Forrest J, Cahalan M, Rehder K, et al: Multicenter study of general anesthesia. II. Results. Anesthesiology 1990; 72:262-268
79. Forrest J, Rehder K, Cahalan M, et al: Multicenter study of general anesthesia. III. Predictors of severe perioperative adverse outcomes. Anesthesiology 1992; 76:3-15
80. Falk JA, Kadiev S, Criner GJ, et al: Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5:543-548
81. Salpeter RS, Ormiston TM, Salpeter EE: Cardiovascular effects of β-aǵonists in patients with asthma and COPD: A meta-analysis. Chest 2004; 125:2309-2321
82. Calverley PMA, Anderson JA, Celli B, et al: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-89
83. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Available at http://ajrccm.atsjournals.org/cgi/data/178/4/332/DC1/1. Accessed October 25, 2009
84. Xopenex (levalbuterol) inhalation solution [package inser:t]. Marlborough, MA, Sepracor, 2007
85. Byrd BF III, Collins HW, Primm RK: Risk factors for severe bradycardia during oral clonidine therapy for hypertension. Arch Intern Med 1988; 148:729-733
86. Daviss WB, Patel NC, Robb AS, et al: Clonidine for attention-deficit/ hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47:189-198
87. Schwartz E, Friedman E, Mouallem M, et al: Sinus arrest associated with clonidine therapy. Clin Cardiol 1987; 11:53-54
88. Precedex (dexmedetomidine) [package insert] Lake Forest, IL, Hospira, 2008
89. Boyd R, Ghosh A: Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose. Emerg Med J 2003; 20:266-267
90. Lheureux PER, Zahir S, Gris M, et al: Benchto-bedside review: Hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers. Crit Care 2006; 10:212-217
91. Greene SL, Gawarammana I, Wood DM, et al: Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: A prospective observational study. Intensive Care Med 2007; 33:2019-2024
92. Bauman JL, DiDomenico RJ, Viana M, et al: A method of determining the dose of digoxin for heart failure in the modern era. Arch Intern Med 2006; 166:2539-2545
93. McMullin ST, Reichley RM, Watson LA, et al: Impact of a web-based clinical information system on cisapride drug interactions and patient safety. Arch Intern Med 1999; 159: 2077-2082
94. Ng TMH, Bell AM, Hong C, et al: Pharmacist monitoring of QTc interval-prolonging medications in critically ill medical patients: A pilot study. Ann Pharmacother 2008; 42: 475-82
95. Reichley RM, Seaton TL, Resetar R, et al: Implementing a commercial rule base as a medication order safety net. J Am Med Inform Assoc 2005; 12:383-389